Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis.

[1] Bailey MS(2007)Cutaneous leishmaniasis Clin Dermatol 25 203-211

[2] Lockwood DN(2006)First finding of Lutzomyia tihuiliensis (Diptera: Psychodidae) in the Valle de Aburra, Colombia Biomedica 26 228-231

[3] Bejarano EE(2009)Interventions for American cutaneous and mucocutaneous leishmaniasis Cochrane Database Syst Rev 2 CD004834-1554

[4] Sierra D(2007)Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis Clin Infect Dis 44 1549-522

[5] Perez-Doria A(1996)Treatment of New World cutaneous and mucosal leishmaniases Clin Dermatol 14 519-614

[6] Velez ID(2009)Leishmaniasis: current treatment and prospects for new drugs and vaccines Curr Med Chem 16 599-1577

[7] Gonzalez U(2005)Advances in leishmaniasis Lancet 366 1561-266

[8] Pinart M(2004)Leishmaniasis: drugs in the clinic, resistance and new developments Drug Resist Updat 7 257-182

[9] Rengifo-Pardo M(2009)Current treatment for cutaneous leishmaniasis: a review Am J Ther 16 178-463

[10] Macaya A(1997)The evaluation of the tolerance and nephrotoxicity of pentavalent antimony administered in a dose of 40 mg Sb V/kg/day, 12/12 hr, for 30 days in the mucocutaneous form of leishmaniasis Rev Soc Bras Med Trop 30 457-667

[1] Bailey MS(2007)Cutaneous leishmaniasis Clin Dermatol 25 203-211

[2] Lockwood DN(2006)First finding of Lutzomyia tihuiliensis (Diptera: Psychodidae) in the Valle de Aburra, Colombia Biomedica 26 228-231

[3] Bejarano EE(2009)Interventions for American cutaneous and mucocutaneous leishmaniasis Cochrane Database Syst Rev 2 CD004834-1554

[4] Sierra D(2007)Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis Clin Infect Dis 44 1549-522

[5] Perez-Doria A(1996)Treatment of New World cutaneous and mucosal leishmaniases Clin Dermatol 14 519-614

[6] Velez ID(2009)Leishmaniasis: current treatment and prospects for new drugs and vaccines Curr Med Chem 16 599-1577

[7] Gonzalez U(2005)Advances in leishmaniasis Lancet 366 1561-266

[8] Pinart M(2004)Leishmaniasis: drugs in the clinic, resistance and new developments Drug Resist Updat 7 257-182

[9] Rengifo-Pardo M(2009)Current treatment for cutaneous leishmaniasis: a review Am J Ther 16 178-463

[10] Macaya A(1997)The evaluation of the tolerance and nephrotoxicity of pentavalent antimony administered in a dose of 40 mg Sb V/kg/day, 12/12 hr, for 30 days in the mucocutaneous form of leishmaniasis Rev Soc Bras Med Trop 30 457-667